

**13 October 2010**

## **Resolutions Passed at the 2010 Annual General Meeting**

At the Annual General Meeting of Biomedical company, **Tissue Therapies Limited (ASX: TIS)** held on 13 October 2010 the following resolutions were passed on a show of hands:

### **2. Directors' Remuneration Report**

*'That the section of the Directors' Report dealing with the remuneration of the Company's Directors, Company Secretary and Senior Executives (**Remuneration Report**) be adopted.'*

### **3. Re-election of Melvyn Bridges**

*'That Melvyn Bridges, who retires in accordance with Listing Rule 14.4 and Rule 16.1 of the Company's Constitution, and being eligible, and having offered himself for re-election, be re-elected as a Director of the Company.'*

### **4. Re-election of Dr Cherrell Hirst**

*'That Dr Cherrell Hirst, who retires in accordance with Listing Rule 14.4 and Rule 16.1 of the Company's Constitution, and being eligible, and having offered herself for re-election, be re-elected as a Director of the Company.'*

### **5(a) Approval of Issue of Options to a Director**

*'That, pursuant to section 208(1)(a) of the Corporations Act and Listing Rule 10.14, and in accordance with the Company's Equity Option Plan, the members of the Company approve the granting of 250,000 options to Dr Steven Mercer, Executive Director and Chief Executive Officer, in the manner outlined in the Explanatory Memorandum''*

### **5(b) Approval of Issue of Options to a Director**

*'That, pursuant to section 208(1)(a) of the Corporations Act and Listing Rule 10.14, and in accordance with the Company's Equity Option Plan, the members of the Company approve the granting of 250,000 options to Mr Melvyn Bridges, Director, in the manner outlined in the Explanatory Memorandum'*

### **5(c) Approval of Issue of Options to a Director**

*'That, pursuant to section 208(1)(a) of the Corporations Act and Listing Rule 10.14, and in accordance with the Company's Equity Option Plan, the members of the Company approve the granting of 250,000 options to Dr Cherrell Hirst, Director, in the manner outlined in the Explanatory Memorandum'*

## 6. Ratification and Approval of Previous Allotment and Issue of Shares

*‘That for the purposes of Listing Rule 7.4 and for all other purposes, approval be given for the previous issue of approximately 3,288,513 shares at an issue price of \$0.1184 per share, issued under a placement to sophisticated and institutional investors as detailed in the Explanatory Memorandum.’*

### Summary of Proxy Votes Lodged

Resolution Name	For	At Discretion of Proxy Holder	Against	Abstain
2	38,319,214	1,797,921	420,864	796,874
3	39,457,741	1,777,921	81,931	17,280
4	39,461,741	1,781,921	77,931	13,280
5 (a)	32,183,656	448,745	481,316	58,844
5(b)	32,030,946	499,251	541,413	100,410
5(c)	31,660,622	499,251	941,940	70,207
6	36,889,633	1,832,064	757,045	493,431

Further information:

Dr Steven Mercer  
CEO, Tissue Therapies Limited  
Telephone: +61 (0)7 3839 9938

Email: [s.mercer@tissuetherapies.com](mailto:s.mercer@tissuetherapies.com)

## About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell-based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)